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ABSTRACT 
Fresh blood specimens were obtained from a normal subject 
and a haemophilia B patient for DNA extraction. The blood 
samples were centrifuged to collect the lymphocytes and 
leucocytes which were lysed with sodium dodecyl sulphate. 
After enzyme digestions by Proteinase K and RNase, DNA was 
extracted by subsequent treatment with sa l t saturated phenol 
and phenol/chloroform (1:1). Genomic DNA was then 
precipitated by isopropanol and spooled out with a sealed 
pasteur pipette• The purity and quantity of DNA was 
determined by uv spectrophotometry and agarose gel 
electrophoresis. 
A polymerase chain reaction (PCR) was established for 
amplification of a DNA fragment of the promoter region of 
the Factor IX (FIX) gene using the extracted genomic DNA as 
templates. Two pairs of 3' and 5' oligonucleotides flanking 
the FIX gene promoter were used. I optimized the PCR 
conditions including primer concentrations, template 
concentrations, MgCl2 concentration, and temperature 
programme • The DNA products amplified by PCR were then 
purified by three methods: glassmilk adsorption using a 
commercially supplied GENECLEAN Kit, glasswool exclusion 
method and extraction from polyacrylamide gel af ter 
electrophoresis. By the f i r s t two methods, I obtained very 
poor yield and the DNA materials were fragmented af te r many 
t r i a l s . Only the third method produced DNA samples that could 
be used for subsequent experiments. 
Direct sequencing of the PCR DNA was attempted using a 
commercially supplied
 35
Sequencing k i t . Only very weak 
signals were obtained af ter several t r i a l s . Another protocol 
u t i l iz ing the dideoxynucleotide termination method was 
attempted using reagents made up by myself. Slightly better 
signals were obtained but s t i l l no convincing readable 
sequence could be produced. Attempts to clone the PCR DNA 
into Ml3 phage vector for transformation in competent cel ls 
were unsuccessful• 
Because of the time constraint and of other limitations in 
f a c i l i t i e s of my laboratory which was newly established for 
molecular cloning, experiments described above were not 
proceeded fur ther . The cloning experiments should be 
produce adequate amount of the FIX DNA by PCR for 
elucidation of the sequence, 
1• INTRODUCTION 
Human Blood Clotting Cascade 
The human blood clott ing reactions involve three major 
steps: Firs t ly , an i n i t i a l step in which an activator i s 
generated that activates prothrombin. A second step in which 
th is prothrombin activator converts prothrombin to thrombin, 
then followed by the third step in which thrombin converts 
fibrinogen to f ibr in [1]. 
Two clott ing systems for converting prothrombin to thrombin, 
the in t r ins ic and extrinsic systems, have been described [2] 
(Fig. 1). The in t r ins ic clot t ing reactions involve the 
factors XII, XI, IX, VIII, X, and V. Factors XII and XI 
involved in the surface activation. Factors V, VIII, and I 
are altered during clot t ing by thrombin. 
The extrinsic clott ing reactions involve the factors VII, x, 
and V which give r ise to an extrinsic prothrombin activator. 
Factor VII, is unique for the extrinsic clot t ing reactions. 
Tissue thromboplastin by-passes the need for factors XII and 
XI and forms a calcium-dependent complex with factor VII, 
which activates factor X. In th i s extrinsic activation of 
factor X, the protein portion of the t issue thromboplastin 
molecule substitutes for factor VIII; and factor VII 
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Fig. 1 The human c lo t t ing cascade showing the i n t r i n s i c 
and ext r ins ic c lo t t ing systems. 
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thromboplastin and factor VII bypasses the requirement for 
the two antihaemophilie factors: factors VIII and IX. 
Blood Clotting Disorders 
Hereditary bleeding disorders caused by reduced clot t ing 
act ivi ty of each of the plasma clot t ing factors have been 
identif ied [3 ]. These disorders may stem from two types of 
genetic defects: a mutation that prevents synthesis of a 
clot t ing protein (for example, fa i lure to synthesize factor 
VIII in von Willebrand's disease), or a mutation that causes 
synthesis of an abnormal molecule with impaired clot t ing 
act ivi ty (for example, the abnormal factor VIII molecules 
lacking factor VIII clot t ing act ivi ty in haemophilia A). The 
patient with factor XII deficiency may have no history of 
abnormal bruising or bleeding, even af ter surgery, but has 
an extremely prolonged clot t ing time in a glass tube, more 
prolonged than blood specimens from many patients with 
severe haemophilia. The haemophilias, factor XI deficiency, 
and factor XII deficiency affect in t r ins ic clot t ing, whereas 
factor VII deficiency impairs only extr insic clot t ing. 
Prothrombin deficiency, factor X deficiency, and factor V 
deficiency affect both in t r ins ic and extrinsic clot t ing. 
Haemophilia A (factor VIII deficiency) and haemophilia B 
(factor IX deficiency) have similar c l inical features and 
clotting abnormalities in screening t e s t s [4]. The cl inical 
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hallmarks of both haemophilias A and B are (1) lack of 
excessive haemorrhage from minor cuts or abrasions, because 
plate le t function is normal, (2) joint and muscle 
haemorrhages leading to d i f f i cu l t and disabling long-term 
sequelae, (3) easy bruising, and (4) prolonged and 
potentially fa ta l post-operative haemorrhage. In general, a 
prolonged whole blood clot t ing time, prolonged activated 
par t ia l thromboplastin time (APTT), and an elevated level of 
residual serum prothrombin may suggest that the patient i s a 
haemophiliac. To confirm the case, further investigation of 
clott ing factors including the measurement of factors VIII 
and IX act ivi ty as well as the i r antigen levels i s available 
in most hospital . A more detailed c lass i f icat ion of 
haemophilia variant which requires techniques of molecular 
genetics i s seldom done. 
Haemophilia A is an X-linked recessive bleeding disorder 
at tr ibutable to decreased blood levels of functioning 
procoagulant factor VIII. This disorder accounts for 
approximately 80% of true haemophilas [5]. 
Haemophilia B i s also an X-linked recessive bleeding 
disorder which can occur in a severe, moderate, or mild 
form, depending on the level of factor IX (FIX) act ivi ty in 
plasma [6,7]. The severe form has a FIX level of less than 
1 %
 of normal? almost half of the haemophilia B patients 
belong to th i s group [8]. The clot t ing time in these 
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patients i s usually longer than 1 hour. In moderate 
haemophilia B case, the FIX level i s 1% to 4%, and the 
clott ing time i s about 20 to 30 minutes« The FIX act ivi ty in 
mild haemophilia i s 5% to 25% of normal； these patients have 
sl ight ly prolonged clot t ing times. Lower levels of FIX have 
been found in carr iers of haemophilia B. Patients with mild 
deficiency of FIX (generally have greater than 5% factor 
activity) have l i t t l e spontaneous bleeding. The incidence of 
haemophilia B i s 1 in 30,000 Caucasian males [9]. 
Biochemistry of Factor IX 
Human coagulation FIX i s also called anti-haemophilic 
factor , Christmas factor , or plasma thromoplastic 
component (PTC) . I t i s a vitamin K-dependent single-chain 
glycoprotein that part icipates in the intermediate stage of 
blood coagulation [5]. I t i s synthesized in the l iver and 
circulates in the blood as a zymogen which i s cleaved by 
serine protease• Factor IX contains twelve -carboxyglutamic 
acid residues (Gla). The Gla residues play an important role 
in calcium binding in the clot t ing process. They can also be 
found in other vitamin K-dependent clot t ing factors such as 
factors I I , VII and X, and proteins C and S. The molecular 
weight of FIX is 55,000 daltons and the biological ha l f - l i f e 
i s about 18 to 24 hours. 
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FIX can be activated either by factor XIa or factor Vila 
plus t issue factors to form activated factor IX (FIXa). In 
the presence of Ca
++
 , factor VIII and pla te le t phospholipid 
molecules, FIXa can form a "factor X converting complex". 
This complex converts factor X into factor Xa and ultimately 
resul ts in the formation of the f ibr in clot [10]. 
Structure of the Factor IX Gene 
The human FIX gene i s located at locus Xq 27.3 on the d is ta l 
long arm of the X chromosome and i s primarily expressed in 
the l iver [11]. I t i s 34 kbases long with eight exons and 
seven introns. Both the FIX gene and the cDNA copy of factor 
IX mRNA have been cloned and sequenced [12,13,14]. The 8 
exons have been shown to encode separate domains in the FIX 
protein (Fig. 2) which are: (a) a hydrophobic signal peptide 
for controlling protein secretion from the hepatocyte into 
the blood stream; (b) a propeptide and Gla domain for post-
translat ional r-carboxylation of 12 glutamic acid residues 
in the Gla region; (c) a small hydrophobic domain for 
promoting heterodimerisation of Gla domains of unrelated 
clot t ing factors [15]; (d) a type B, epidermal growth 
factor-l ike domain, which i s homologous to epidermal growth 
factor (EGF). This domain binds an additional Ca
2+
 with high 
a f f in i ty and may also bind to factor VIII. (e) A type A, 
epidermal growth factor-l ike domain which i s similar to exon 
d but lacks the homologous carboxylate residues; (f) the 
activation domain includes the 35-residue peptide that i s 
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Fig. 2 The human factor IX gene showing the eight exons, 
the introns, position of the promoter and the poly 
(A) s i t e . 
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removed during zymogen activation, (g) and (h) the serine 
protease domain, responsible for the proteolysis. The active 
s i t e of FIX i s contained within the serine protease domain, 
which i s supported by 6 other signalling regions. The active 
s i t e His -221 i s in exon g, but the other two active s i t e 
residues, Asp -269 and Ser -365 residues of the charge relay 
system of the active s i t e , and Asp -359 of the substrate 
binding pocket, are a l l in exon h. This type of arrangement 
i s different from those other serine proteases. The eight 
domains mentioned above play different roles which are 
essential either for biosynthesis, modification, activation 
by XIa or for ensuring maximal cata lyt ic act ivi ty [12]. 
Molecular Defects of the Factor IX Gene 
There i s a wide variation in terms of molecular defect in 
haemophilia B patients [16]. For patients catergorised as 
antigen positive, point mutations in the FIX gene coding 
region result ing from mild, moderate, and severe bleeding 
disorder. In the antigen negative group, either deletions or 
point mutations for the correct biosynthesis of messenger 
RNA or the protein i s affected severely. Point mutation i s 
characterized by a single base pair change, i t may be a base 
substi tution, a base insert ion, or a base deletion. A 
database with 221 entries l i s t s a l l known point mutations 
and short deletions and additions in the FIX gene has been 
established [17]. Of the 216 known mutations within the 
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gene, 115 are unique molecular events, the remainder being 
repeats. Most of the repeats occur at CG dinucleotides and 
involve a CG-^TC or CA change which can be considered as 
'hotspots ' . Mutations have been detected in a l l domains and 
control regions within the gene, except the signal peptide 
and poly (A) s i t e . On the basis of prolonged ox brain 
prothrombin time measurement, a haemophilia Bm variant i s 
identif ied [18]. 
A rare type of haemophilia B, the Leyden form, has also been 
described [19,20]. Patients with th i s type of bleeding 
disorder show severe symptoms in childhood. However, FIX 
level i s r is ing with increasing age and progressing to a 
mild or an asymptomatic condition af te r puberty. The FIX 
level may r i se from less than 1% in early childhood before 
puberty to more than 50% of normal a f te r puberty. Another 
less severe form of haemophilia B Leyden, namely, 
haemophilia B High Wycombef with different G—A mutation at 
-6 has also been described [21] 
The use of polymorphic DNA markers usually can determine the 
parental source of each X chromosome [22,23]. Restriction 
fragment length polymorphism (RFLP) with intragenic 
oligonucleotide markers has been used for diagnosis of 
carr ier s ta te and claimed to be with 99.9% r e l i ab i l i t y [24]• 
With intragenic RFLPs, the resul ts obtained are essential ly 
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qualitative and are easily interpretable for both carr ier 
detection and prenatal diagnosis. However, important 
differences have now been shown between the Chinese and 
Caucasian populations. None of the four RFLPs (Taq-j-, Dde工， 
Xmrij, and Msp工)can be used for family studies and prenatal 
diagnosis in the Chinese population of Jiangsu province 
[25]. 
The advent of polymerase chain reaction (PCR) technique 
makes i t possible to amplify the genomic DNA for higher 
yield of product to be able to perform direct sequencing 
[26]. Substitution of Cys 336 and Asn 120 as well as 
deletion of Arg 37 lead to the decreased level of FIX 
antigen, whereas in the substitution of Arg - 4 , Arg 333, Asp 
64 and Pro showed no significant reduction of protein serum 
levels. These abnormalities are identified by direct 
sequencing of amplified genomic DNA which overcome the 
limitation of heterozygote and marker required in RFLP 
[16] • Other methods such as dimethyl sulphoxide and 
amplification and mismatch detection have been introduced to 
improve direct sequencing and thus enhance the intensity of 
signal [27,28]. 
T h e F a c t o r I X P r o m o t e r 
Mutations in promoters affect the level of expression of the 
gene(s) they control, without al tering the gene products 
themselves. Almost a l l of the point mutations that affect 
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promoter function f a l l within the two consensus sequences 
which located at -35 and -10 with consensus sequences TTGACA 
and TATAAT respectively [29]. I t has been demonstrated that 
a consensus TATA box, and sometimes a CCAAT box [30] and 
further upstream sequences are significant for eukaryotic 
promoters. However# neither TATA box nor CCAAT are observed 
in the FIX promoter [13]. All cases of haemophilia B Leyden 
reported in the database of point mutations [17] show 
abnormality in the promoter region, therefore i t i s a region 
of in teres t in FIX gene study. More new mutations are 
expected to be found in the FIX promoter, part icularly in 
non-Leyden haemophilia B patients . 
Although there i s no report on incidence rate of haemophilia 
B in Chinese, reports of studies on FIX deficiency in 
Jiangsu Province suggested a possible high frequency in that 
area, which i s situated in the middle part of china. 
However, haemophilia B i s not regarded as prevalent in Hong 
Kong, where the population i s mostly Southern Chinese. 
Moreover, studies on 七he FIX promoter in Chinese has not 
been reported. I intend to investigate the promoter 
sequence in a Chinese haemophilia B patient born in Hong 
Kong. 
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2 • OBJECTIVE 
To establish protocols of DNA extraction, polymerase chain 
reaction and sequencing for comparison study of the FIX promoter 
sequence of a haemophilia B patient and a normal subject. 
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3. MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Enzymes 
1. Protease (Proteinase K) Type XXVIIII from Tritirachium 
album (Sigma) 
2. Ribonuclease A (Ribonuclease 工 ； E C 3.1.27.5) Type XII-
A: from Bovine Pancreas (Sigma) 
3. Taq DNA polymerase (Pharmacia) 
4. T4 DNA ligase (Amersham) 
5. Alkaline phosphatase (calf in tes t ina l mucosa) 
(Pharmacia) 
6. Restriction Endonuclease Sma I (Amersham) 




3.1.2 DNA Markers 
1- Hae I I I Digest 0X-174-RF DNA (Pharmacia) 
2. DNA Hind I I I Digest (Pharmacia) 
3. PATX Hinq (self-prepared) 
4. Hae I I I Digest pBR322 DNA (Sigma) 
3.1.3 General Reagents 
Acrylamide (Sigma) 
Agarose (Sigma) 
Amberlite, Mixed Bed Resin TMD-8 (Sigma) 
Adenosine triphosphate (ATP) 
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Bovine serum albumin (Sigma) 
Bromphenol blue (Merck) 
Chloroform (BDH) 
Dideoxynucleotide triphosphate (ddNTP) set 5mM solutions 
(Pharmacia) 
Deoxynucleotide triphosphate (dNTP) set lOOmM solutions 
(Pharmacia) 
Dimethyl sulphoxide (DMSO) 
Dithiothreitol (Merck) 
Ethidium bromide (Sigma) 




Isopropyl 13-D-Thiogalactopyranoside (IPTG) (Sigma) 
2-Mercaptoethanol (Merck) 
N,N-Methylene diacrylamide (Merck) 
N,N,N〜N'-tetramethyl ethylenediamine (TEMED) (Sigma) 
Paraffin liquid (Merck) 
Phenol (Merck) 
Trizma base, Purity 99.9% (Sigma) 
Trizma hydrochloride (Sigma) 
Xylene cyanol FF (Sigma) 
X-Gal (5-bromo-4-chloro-3-indolyl-fi-D-galactoside) (Sigma) 
Other reagents are either of Biochemical or Anala R grade 
from Sigma, BDH or Merck. 
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3•2 General Methods 
3.2.1 Preparation of Phenol and Phenol/Chloroform (1:1) 
Phenol (400 g) was dissolved in 400 ml 0.1 M Tris buffer, pH 
8.0, by constant s t i r r ing . The upper aqueous layer of Tris 
was then aspirated, and hydroxyquinoline was added to the 
organic phase to give a f inal concentration of 0.1% (w/v). 
Equal volume of 0.1 M Tris buffer, pH 8.0 was added, the 
mixture was s t i r red and the upper aqueous layer was then 
aspirated. This step was repeated five times. Finally, a 
0.2% 6-mercaptoethanol in 1:10 (v/v) Tris, pH 8.0, was added 
and the liquid phenol was stored in an amber bott le at 4°C 
for up to one month. 
For the preparation of 1:1 phenol/chloroform, 400 g phenol 
was dissolved in 400 ml 0.1 M Tris pH, 8.0 and 
hydroxyquinoline was added. Equal volume of chloroform as 
the phenol layer was added. The mixture was s t i r red and the 
upper aqueous layer aspirated. This procedure was repeated 
five times. Finally, 13-mercaptoethanol was also added and 
the solvent mixture was stored in an amber bott le at 4。C. 
3.2,2 Buffer preparation 
10 X TBE Buffer, pH 8.4: 0.9 M Tris 
0.89 M Boric acid 
25 mM EDTA 
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50 X TAE Buffer, pH 8.0: 2 M Tris base 
5.7% Acetic acid 
50 mM EDTA 
TE Buffer^TEn: 10 碰 Tris, pH 8.0 
0.1 mM EDTA 
TEX ^  0 : 10 mM Tris, pH 7.4 
lm M EDTA 
RNase Buffer pH 7.4: 10 mM Tris 
15 mM NaCl 
Gel-loading Buffer: 0.25% Bromphenol blue 
0.25% Xylene cyanol FF 
15% Ficoll 
ACD Solution: 23 mM Citr ic acid 
45 mM Sodium c i t r a t e 
82 mM Glucose 
Lysing Buffer 1: 100 mM NaCl 
1 mM EDTA 
10 mM Tris, pH 8.0 
0.5% SDS 
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Lysing Buffer 2: 100 raH NaCl 
5 mM EDTA 
100 mM Tris, pH 8.0 
0.5% SDS 
T4 Ligase Buffer: 300 mM Tris, pH 7.8 
100 mM MgCl2 
100 mM DTT 
10 mM ATP 
Amplification Buffer: Stock amplification buffer 
0.18 M (NH4)2S04 
88 mM MgCl2 
0.74 M Tris, pH 8.8 
Working buffer (10 X buffer 8) 
89 /il amplification buffer 
10 /il 10 mg/ml BSA 
1 Atl 6-mercaptoethanol 
This working buffer was prepared freshly for each PCR. 
5 X Sequenase Buffer: 200 mM Tris, pH 7.5 
100 mM MgCl2 
250 mM NaCl 
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3.2.3 Agarose Gel Electrophoresis 
Horizontal agarose gel electrophoresis was carried out on a 
'homemade' perspex apparatus. One percent gel was prepared 
by dissolving 3 g agarose in 300 ml 1 X TBE or 1 X TAE 
buffer, followed by melting in a microwave oven. After 
adding 5 jLtl of 10 mg/ml ethidium bromide, appropriate 
amount of the gel was poured into an electrophoresis tray 
for sol id i f ica t ion. Wells on the gel were formed with a 
comb. After sol idif icat ion and loading of DNA markers and 
samples, electrophoresis was carried out in an 
electrophoresis tank* Voltage of 1-5 V/cm was applied unt i l 
bromphenol blue and xylene cyanol FF were migrated to 
appropriate distance on the gel- Photograph was taken under 
uv l ight on Polaroid film. 
3.2.4 Polyacrylamide Gel Electrophoresis (PAGE) 
Native polyacrylamide gel was carried out on a Protean 工工 
gel apparatus (BioRad, Richmond, CA, USA). Denaturing 
polyacrylamide gel was carried out on a 'homemade' ver t ical 
gel apparatus. 
Preparation of Stock Acrylamide Solution 
10/9 20% Native acrylamide stock 
One hundred and ninety g acrylamide and 10 g N,N methylene 
bisacrylamide were added into 900 ml d i s t i l l ed water. 
Deionization was carried out by adding one tablespoonful of 
Amberlite monobed resin, followed by mixing and f i l t e r ing . 
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The 5% Native PAGE gel was prepared; 
5 ml 10/9 20% native acrylamide 
2 ml 10 x TBE 
13,8 ml water 
200 /il 10% ammonium persulphate 
20 ill TEMED 
Preparation of Denaturing Polyacrylamide Gel 
A 30% denaturing PAGE gel for sequencing was prepared by 
dissolving 28.5 g acrylamide and 1.5 g bis-acrylamide in 100 
ml deionized. H20. 
To prepare 7 M urea in 5% polyacrylamide gel, 63 g of urea 
was combined with 15 ml of 10 X TBE and 25 ml of 30% 
acrylamide stock solution. The to ta l volume was adjusted to 
150 ml with d i s t i l l ed water. I t was then f i l t e red through an 
0.45 micron mesh f i l t e r and degassed. 
3.3 DNA Extraction 
3.3.1 Haemophilia B Patient 
The haemophilia B patient WPC is a seventeen years old male 
patient. When he was at 3 years of age he suffered minor 
head trauma with persistent oozing from the mouth. Activated 
par t ia l thrombin time was prolonged to 134 seconds (control 
45 seconds) which was corrected by serum, indicating a 
possible FIX deficiency. However no FIX assay was available 
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at that time. Since then, he had 4-5 haemorrhagic episodes 
per year mainly of haemarthrosis, muscle bleeding and gum 
bleeding occasionally treated by fresh frozen plasma or 
prothrombin concentrates. One year ago, his APTT was 
measured again and i t was 88 seconds. FIX level was also 
checked. Unfortunately, the resul t was somehow 
unretrievable. Nevertheless, the word "low FIX activi ty" was 
recorded in the patient record. 
3.3.2 Blood Collection 
Five mxl l i l i t res blood was collected from a male normal 
subject (CPP) and the haemophilia B patient (WPC) by venous 
puncture into a sample tube containing 1.7 ml ACD solution. 
3.3.3 DNA Extraction 
The blood specimens (5 ml whole blood in 1.7 ml ACD) were 
centrifuged at 3000 X g for 10 minutes. Plasma was discarded 
by aspiration and about X-5 ml buffy coat was collected. 
Lysing buffer 1 (2.5 ml) was added and the mixture was 
vortexed for 2 minutes. About 1 mg proteinase K was added. 
The sample mixture was incubated at 55°C for 1 hour then at 
37°C overnight under constant shaking. In the next day 0.1 
mg RNase was added and the sample mixture incubated at 37。C 
for another 10 minutes. An equal volume of phenol was added 
and the sample vigorously vortexed for 10 minutes followed 
by centrifugation at 8000 X g for 15 minutes. This step was 
repeated once followed by two extractions by 
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phenol/chloroform (1:1). DNA was spooled out with sealed 
pasteur pipette af te r addition of 2 volumes of isopropanol. 
The DNA obtained was dissolved in 300 /il TE^^ Q . 
If the DNA obtained showed high absorption at 280 nm i t 
would be taken for further digestion by proteinase K and 
RNase and re-extraction by phenol and phenol/chloroform. 
Three DNA samples were prepared from blood samples taken 
from the normal subject CPP and were labelled as CPP-1, CPP-
2 and CPP-3. One DNA sample was prepared from the patient , 
labelled as WPC-1, 
3.3.4 DNA Quantitation 
DNA was quantitated by uv-spectrophotometry on a Response 
Spectrophotometer (Gilford, Oberlin, Ohio, USA). Absorption 
at wavelength 260 nm and at 280 nm was taken. The reading at 
260nm allowed calculation of the concentration of nucleic 
acid in the sample. An optical density (OD) of 1 corresponds 
to approximately 50 jug/ml of double-stranded DNA, 40 n g / m l 
single-stranded DNA, and 20 jug/ml single-stranded 
oligonucleotides. The ra t io between the absorbance a t 260nm 
and 280nm (〇D260/OD280) provides an estimate of the purity 
of the nucleic acid. 
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3.3.5 Polymerase Chain Reaction (PCR) 
Polymerase chain reaction was carried out on a PCR 
TempCycler (Coy, Ann Arbor, Michigan, USA). Four 
oligonucleotides were kindly provided by Professor George 
Brownlee, Sir William Dunn School of Pathology, University 
of Oxford. They were used as primers for both PCR and 
sequencing of the FIX promoter. Different combinations of 
primers were tested for annealing. (Fig. 3) 
101 5' upstream sequence 
5'-GTGCT GCCAC AGTAA ATGTA-3' 
102 - - 3' downstream sequence 
5'-TGATG AGGCC TGGTG ATTCT-3
 7 
103 - - 5' upstream sequence 
5'-GCCTA TCTCC ATTCT GA-3' 
104 — 3' downstream sequence 
5'-GCACT GAGTA GATAT CCTAA AAG-3' 
Human genomic DNA from a normal subject - - samples CPP-1, 2 
and 3, and a haemophilia B patient - - sample WPC-1, were 
used as templates. 
Optimization of PCR 
A series of experiments (PCR-1 to PCR-7) have been carried 
out to obtain the optimal amplification conditions. The PCR 
products obtained af ter each experiment was analysed by 5% 
(w/v) polyacrylamide gel electrophoresis. 
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101 103 
2708 ^2728 2737 ^2753 
B^ B^BSSZ^ H^na^HBBBBMIIIIBHBmHBaiBBBHaaaBBIBIBaaHaaBaBHBBaHBBIBiaaBI 
•MBBazMimii—iMmMa asaiMEigaaiMBgmjia^—1——^M— 
3021 t 3040 3049^ 3071 
102 104 
Fig. 3 Position of the 2 pairs of primers, #101 and #102, 
and #103 and #104 on the FIX promoter sequence. 
The numbering system is that used in [14 ]. PCR 
products obtained from primers #101 and #102 has a 
length of 332 bp and that from primer #103 and 
#104 also a length of 334 bp. 
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N 
PCR-1: In i t i a l set up. 
/ 
To a 0.5 ml PCR reaction tube was added 5 /zl 10 X buffer 8, 
5 jLtl 15 mM dNTP, 2 /il primer 101 (200 ng) and 2 primer 
102 (200 ng). DNA templates and water were then added. 
Sample DNA Template Water 
PCR-1-1 Nil 36 nl 
PCR-1-2 CPP-1: 2 /il (320 ng) 34 /il 
PCR-1-3 CPP-1: 5 /il (800 ng) 31 fj.1 
The final volume of each reaction mixture was 50 fil and 50 
/il paraffin oi l was layered on top to prevent evaporation. 
After incubation at 95
9
C for 7 minutes, 1.25 units Taq DNA 
polymerase 1 /il was added to each sample. The reaction 
mixture was vortexed gently and. centrifuged briefly before 
being placed into the TempCycler. Sample holding blocks of 
the TempCycler were f i l l ed with glycerol to provide uniform 
heating. The temperature programme was set as: 
Denaturing temperature: 91°C, 1 min 
Annealing temperature: 60。C, 1 min 
Extension temperature: 65。C, 3 min 10 sec 
Number of cycles: 30 
PCR-2: Optimization with different temperature programme 
The same sample mixtures were prepared as in PCR-1 but were 
labelled as PCR-2-1, PCR-2-2, and PCR-2-3. This i s because 
PCR was carried out using a temperature programme which i s 
different from that of PCR-1. 
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Denaturing: 9 1 1 rain 
Annealing: 60°C, 1 min 
Extension: 65°C, 3 min + 10 sec 
Number of cycles: 30 
In th i s programme, each,cycle was edited separately to allow 
10 additional seconds to the extension period. Hence7 cycle 
1 was edited for 3 minutes at 65。C for extension, cycle 2 
for 3 minutes 10 seconds, cycle 3 for 3 minutes 20 seconds, 
etc, for up to 30 cycles. 
PCR-3: Optimization of PCR using two d i f fe ren t MgCl2 
concentrations 
In th i s experiment, a d i f ferent Mg(II) concentration, 0.78 
mM was used in the f ina l PCR reaction mixture instead of 
7.8 mM in the previous PCR and 200 ng of each primer was 
used for each reaction. 
Sample DNA Template Primers MgCl2 Water 
200ng) 
PCR-3-1 Nil 102&103 7.8 mM 36 jLil 
PCR-3-2 CPP-1: 1 jLtl (161 ng) 102&103 7.8 mM 35 /il 
PCR-3-3 WPC-1： 3 /il (198 ng) 102&103 7,8 mM 33 /^ 1 
PCR-3-4 Nil 103&104 0.78 mM 36 /xl 
PCR-3-5 CPP-l: 1 ill (161 ng) 103&104 0.78 mM 35 /il 
PCR-3-6 WPC-1： 3 /il (198 ng) 103&104 0.78 mM 33 /il 
Taq DNA polymerase: 2.5 units 
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Temperature programme: 
Denaturing: 95°C, 2.5 min 
Annealing: 60
0
C, 2.5 min 
Extension: 70°C, 4 min 
Number of cycles: 30 
PCR-4: PCR with different programme and primers 103 and 104 
Sample DNA Template Primers Water 
PCR-4-1 Nil 2 jLil (200 ng) 36 /il 
PCR-4-2 CPP-l: 4 jLil (560 ng) 2 /il (200 ng) 32 fxl 
PCR—4-3 WPC-1: 8 Ml (528 ng) 2 /il (200 ng) 28 /il 
PCR-4-4 CPP-3: 8 jLil (560 ng) 2 fil (200 ng) 28 jLtl 
Taq DNA polymerase: 2.5 units 
Temperature programme: 
Denaturing: 9 3 ° C , 2 rain 
Annealing: 60°C, 2 min 
Extension: 65°c 3, 4, 5, 6 , 7 , or 8 min 
Using the same TempCycler, six separate profi les were 
edited, each with the same set of parameters except that the 
period of the extension increased from 3 to 8 minutes. Each 
profi le was then run for 6 cycles, i . e . the f i r s t 6 cycles 
had an extension period of 3 minutes and the next 6 cycles 
for 4 minutes, etc. In th i s programme, a to ta l of 36 cycles 
were run. 
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PCR-5: PCR with primers 101 and 102 
Oligonucleotides 101 and 102 were used as primers, 80 ng 
each, otherwise the composition of WPC-1 and CPP-3 samples, 
the temperature programme and the number of cycles were the 
same as in PCR-4. 
PCR-6: Optimization using di f ferent amounts of templates 
Sample DNA Template Primers Water 
PCR-6-1 Nil 10 jLtl (400 ng) 20 jLil 
PCR-6-2 CPP-2: 2 ill (140 ng) 10 /il (400 ng) 18 j i l 
PCR—6—3 CPP-2: 4 jLtl (280 ng) 10 /il (400 ng) 16 jLtl 
PCR-6-4 WPC-1: 2 ill (130 ng) 10 /il (400 ng) 18 /xl 
PCR-6-5 WPC-1: 4 jLtl (260 /il) 10 /il (400 ng) 16 /il 
Taq DNA polymerase: 2.5 units 
The temperature programme was same as in PCR-4. 
PCR-7: Optimization using a di f ferent PCR machine 
Sample DNA Template Primers Water 
PCR-7-1 Nil 10 /il (400 ng) 20 jLtl 
PCR-7-2 CPP-2: 2 jLtl (140 ng) 10 jLtl (400 ng) 18 /il 
PCR-7-3 WPC-1: 2 ill (130 ng) 10 y.1 (400 ng) 18 /il 
PCR-7-4 CPP-2: 4 jLtl (280 ng) 5 /il (200 ng) 16 /il 
PCR— 7一5 WPC-1: 4 /il (260 ng) 5 /il (200 ng) 16 /il 
PCR-7-6 CPP-2: 8 Ml (560 ng) 10 /il (400 ng) 12 /il 
PCR-7-7 WPC-1: 8 f i l (520 ng) 10 /il (400 ng) 12 /il 
Taq DNA polymerase: 2.5 units 
The temperature programme was same as in PCR-2. 
27 
3.3.6 Purification of PCR Products 
A commercially available GENECLEAN Kit was purchased from 
BIO 101 ( La Jol la , CA, USA) and i t contained the following: 
Nal: 6M sodium iodide solution 
TBE Modifier: a proprietary mixture of concentrated sa l t s . 
NEW Concentrate: for making the NEW wash, 
(NaCl/ethanoi/water)• 
GLASSMILK: a suspension of s i l i ca matrix in water. 
Twenty microlitres of PCR product was electrophoresed in 
1.4% (w/v) agarose gel in 1 X TAE buffer at 50 milliamperes 
for 1 hour, the appropriate DNA band was excised under uv. 
The gel was weighed, put into an eppendorf tube, and added 
with 3 volumes of Nal solution and incubated at 52°C for 
several minutes unt i l the gel was dissolved. Glassmilk, 5 
/il, was added and the mixture incubated on ice for 5 minutes 
and vortexed gently at 1-minute intervals . The suspension 
was then centrifuged at 13000 X g for 5 minutes. The 
supernatant was discarded and the pel le t (DNA) washed by 
200 /il NEW wash thr ice . The DNA adsorbed on the Glassmilk 
was eluted with water. Fi rs t ly , 6 /il of water was added to 
resuspend the pel le t and incubated at 52。C for 3 minutes. 
The supernatant was collected a f te r centrifugation at 13000 
X g for 1 minute. This process was repeated with another 6 
/il of water. The supernatants were combined. DNA content was 
determined by uv spectrophotometry and polyacrylamide gel 
electrophoresis. 
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At times when the GENECLEAN procedure failed to work as 
expected, i . e . , yield of DNA was poor, the following rescue 
procedure was carried out. Twenty microlitres of the PCR 
product was e1ectrophoresed on 1.4% (w/v) agarose gel in 1 X 
TAE buffer. The. gel containing the DNA band was excised 
under uv. Sodium iodide solution, 370 jul, was added 
incubated at 52 °C for 8 minutes. The pH was adjusted to 6 
af ter adding dilute acetic acid. Twenty microlitres of th i s 
solution was kept aside, and 5 /xl Glassmilk suspension was 
added to the res t of Nal/DNA mixture on ice. The suspension 
was mixed gently every minute for 5 minutes. The pel le t 
obtained af te r centrifugation at 13000 X g for 10 seconds 
was washed with the NEW wash thr ice , while the supernatant 
was kept aside. The NEW washes were combined. DNA adsorbed 
” ‘ “ ； 
on the pel le t was eluted by incubation with 10 jllI water at 
52 °C for 5 minutes. The eluate was collected af te r 
centrifugation at 13000 X g for 1 minute. 
Agarose Gel Extraction with Glasswool Exclusion 
PCR product (20 /il) was electrophoresed in 1.4% (w/v) 
agarose gel in 1 X TAE buffer at 50 milliamperes for 1 hour. 
The appropriate DNA band in the gel was excised under uv and 
cut into 5 equal portions. Each gel s l ice was placed into a 
0.5 ml small eppendorf tube containing and 100 fil TE pH 8.0 
(Fig.4). A hole had been punched from the bottom of the tube 
which was stuffed with small amount of siliconized glasswool 
and placed inside a 1.5 ml eppendorf tube. The gel was then 
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allowed to dissolve. The tube assembly was centrifuged at 
13000 X g at 4°C for 5 minutes. Upon centrifugation, eluate 
coming out from the hole of the small tube entered to the 
1.5 ml tube. To the eluate was added 3 M sodium acetate to a 
f inal concentration of 0.3 M and 2.5 volumes of absolute 
ethanol. DNA was precipitated by incubation at -70。C for 1 
hour and pelleted by centrif ugation at 13000 X g for 5 
minutes. After washing with 70% ethanol, the DNA pel let was 
air dried and dissolved in 20 /il TE buffer. 
Polyacrylamide Gel Extraction 
The PCR product (20 /il) was electrophoresed in 5 % (w/v) 
polyacrylamide gel at 60 milliamperes for 30 minutes. The 
gel was treated with ethidium bromide and DNA viewed under 
uv. The DNA band in the appropriate position was excised and 
put into eppendorf tubes. A 100 /il aliquot of 2 M ammonium 
acetate and 5 /il 1% t r i ton X-100 were added. The mixture was 
incubated overnight at 37。C with constant shaking. Equal 
volume of n-butanol was then added and the mixture vortexed 
for 5 minutes and centrifuged at 13000 X g for 1 minute. The 
upper organic layer was aspirated off . To the lower aqueous 
layer was added 60 fj.1 5 M ammonium acetate and 3 volumes of 
absolute ethanol. The mixture was incubated at -20°C for 1 
hour. DNA pellet was collected by centrifugation at 13000 X 
g for 30 minutes, then washed with 500 fil 70% ethanol• The 
DNA sample was a i r dried, and dissolved in 10 /il TE buffer. 
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small tube large tube 
-> — > 
Centrifuge 
- = - n r at 13000 x g 
/ Agarose gel Eluate 
Glasswool
 i n T E b u f f e r 
Fig. 4 Purification of PCR product by agarose gel 
extraction and glasswool exclusion. 
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3.2.10 Sequencing 
The composition of reagents and solutions used in sequencing 
reactions i s detailed as follows: 
ddNTP Mixes 
T Mix： 80 /zM dTTP, dCTP, and dGTP； 8 juM ddTTP; 
50 mM NaCl； 10% DMSO. 
C Mix: 80 juM dTTP, dCTP, and dGTP; 8 juM ddCTP; 
50 mM NaCl； 10% DMSO. 
G Mix： 80 /iM dTTP and dCTP； 8 /iM dGTP and ddGTP； 
50 mM NaCl; 10 % DMSO. 
A Mix： 80 /iM dTTP, dCTP, and dGTP; 0.08 jliM ddATP? 
50 juM NaCl； 10 % DMSO. 
Enzyme Labelling Mix; 2 fil
 35
S-ATP 
0.5 /il sequenase (Klenow Fragment) 
2 /il 100 mM DTT 
1 /il DMSO 
3.5 /il Tris EDTA01 pH 8 
Total volume 9 /il, for 2 reaction. 
Annealing Mix: 0.5 fil 100ng//il primer 
f 
5 /il 5 X sequenase buffer 
2 /il DMSO 
3.5 /il Tris EDTA01 pH 8.0 
Chase Solution: 2 /il 15mM dNTPs 
12 fil DMSO 
106 fil H20 
Total volume 11 / i l , for 2 reactions, 
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Stop Solutions 98% forraamide 
10 mM EDTA 
0.3% (w/v) xylene cyanol 
0.3% (w/v) bromphenol blue 
A commercial S
35
Sequencing Kit purchased from Pharmacia 
(Uppsala, Sweden) was also used, the k i t contained: 
'A' mix: ddATP in solution with dATP, dCTP, dGTP and dTTP 
'C' mix: ddCTP in solution with dATP, dCTP, dGTP and dTTP 
mix: ddGTP in solution with dATP, dCTP, dGTP and dTTP 
mix: ddTTP in solution with dATP, dCTP, dGTP and dTTP 
FPLCpure Klenow Fragment, sequencing buffer, chase solution 
and stop solution. The stop solution was a formamide 
solution containing lOmM EDTA, 0.3% (w/v) xylene cyanol and 
0.3% (w/v) bromphenol blue. 
The gradient of 6% (w/v) denaturing PAGE gel was prepared by 
the following: 
The l ight acrylamide solution (A) contained: 0.5 X TBE/6% 
acrylamide/ 7.67 M urea. The heavy acrylamide solution (B) 
contained 2.5 X TBE/ 6% (w/v) acrylamide/ 7.67 M urea/ 10% 
(w/v) sucrose. Both solutions were f i l t e red and degassed. 
One mi l l i l i t r e s of both acrylamide solutions were added with 
1 nl 25% ammonium persulphate and 1 /i TEMED. Twelve 
mi l l i l i t r e s of l ight solution was pipetted into a 25 ml 
pipette. This was followed by drawing 12 ml of the heavy 
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solution into the same pipette. The gradient interface was 
mixed by a few dislodged bubbles• Contents of th is pipette 
was cast down into the space of the sandwich glasses used • ‘ • 
for gel set t ing. Another 50 ml of l ight solution was layered 
on top. A comb was placed into the gel to form slots for 
sample loading. 
Gel Drying 
The gel af ter electrophoresis was fixed in acetic acid: 
methanol: water (1:1:8 v/v/v) for 15 minutes before being 
transferred to a sheet of Whatman 3 mm paper. I t was dried 
on a Gel Dryer (BioRad, Richmond, CA, USA). 
Autoradiography 
After the gel was completely dried, i t was put into a X-ray 
film cassette and autoradiographed with Du Pont Cronex 
intensifying film by exposure for 16-24 hours at room 
temperature. 
Sequencing Protocol-1 
Steps involved in sequencing are described as follows: 
1
*
 F o u r
 microlitres of a purified DNA as template was 
added to 5 fil annealing mix. After incubation at 95°C 




 which i t was kept for a further 5 minutes. The 
sample was allowed to thaw out at room temperature for 
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10 m i n u t e s . 
2. After adding 4 /il of enzyme labelling mix to the 
sample, the reaction mixture was divided into 4 X 2.5 
Ml portions. Two microlitres of each A, C, G, and T mix 
was added to each of the 4 portions. The samples were 
then incubated at 37°C for 5 minutes. 
3 • Two microlitres of chase solution was added to each 
reaction mixture, which was then incubated at 37。C for 
another 5 minutes. This i s followed by the addition of 
3 /il stop solution. 
4. Each A, C, G, and T reaction mixture was then heated to 
75-80。C for 2 minutes prior to electrophoresis on 6% 
denaturing polyacrylamide gel. 
Sequencing Protocol-2 
This protocol ut i l ized most of the solutions in the 
3
 Sequencing k i t supplied by Pharmacia and the steps 
involved are outlined as follows: 
1. Double-stranded DNA was denatured by incubating a 
mixture of 2 nl DNA solution, 6 /il water and 2 /il 2 M 
NaOH at room temperature for 10 minutes. 
2. To the mixture was added 3 /il 3 M sodium acetate, pH 
4.5, 7 /il d i s t i l l ed H20 and 60 /il absolute ethanol. I t 
was then placed on ice for 5 minutes and transferred to 
liquid N2 for 15 minutes. After thawing the sample was 
centrifuged. The DNA pel le t obtained was washed with 
500 Ml ice-cold 70% ethanol, air-dried and redissolved 
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in 1 ill H20. 
3. Sequencing buffer, 1.5 ill, and 7.5 /il of 100 ng / /il 
oligonucleotide 101 as primer were added/ and the 
sample incubated at 37°C for 20 minutes to allow 
annealing of the primer onto the template. 
4. An enzyme/label/primer/template (ELPT) mixture was 
prepared by adding 3 /xl of FPLCpure Klenow Fragment and 
2 Ml (20 AtCi) of [a-
35
S]dATPaS (600 Ci/mmol) to the 
annealed primer/template from step 3• 
5. Four sequencing reactions were set up 3 /il of each A, 
C, G, and T mixes was put into each labelled tube, to 
which 3 /il ELPT was added. Reaction was in i t ia ted by 
centrifugation of the samples at 13000 X g for 2 
seconds, and proceeded at room temperature for 15 
minutes. 
6
' Towards the end of the incubation period, 1 /il of chase 
solution was placed on the wall of each tube, and was 
allowed to mix with the sample by centrifugation for 2 
seconds. The sample mixtures stood at room temperature 
for 15 minutes. 
1
• Towards the end of th i s second period of incubation, 3 
/il of stop solution was then placed on the wall of each 
tube. Mixing was in i t ia ted by centrifugation to stop 
the sequencing reaction. 
8. The samples were heated at 95 °C for 3 minutes prior to 
electrophoresis on denaturing polyacrylamide gel. 
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3.2.11 Cloning 
The purified PCR product was used as DNA inser t , the 
staggered ends were trimmed with T4 DNA polymerase in the 
following reaction mixture: 
DNA samples 1//1 
T4 DNA polymerase 0.5 /il 
dNTP lOmM 0.5 /il 
T4 polymerase buffer 1 
H20 7 ill 
This mixture was incubated at 30°C for 45 minutes and then 
at 75°C for 10 minutes. 
The vector Ml3 (50 /il) was digested with 2 /il of Sma X 
res t r i c t ion endonuclease, 6 /il of 10 X buffer , and 2 jLtl of 
H
2 ° '
 t h e n
 incubated at 25 °C for 2 hours. A second digestion 
was done by a further addition of 2 /il Sma I , 1 /il 10 X 
buffer and 7 jLtl H20 and incubation at 25。C overnight. The 
七 r e a t e d vector M13 (70 /il) was dephosphorylated by adding 1 
/il of calf in tes t ina l alkaline phosphatase, 8 /zl buffer and 
1 pi H20 and incubating at 37。C for 30 minutes, then at 56°C 
for 30 minutes. An additional 1 fxl alkaline phosphatase was 
added and the reaction mixture was incubated at 37°C for 45 
minutes, then at 56 ° C for 45 minutes. The Ml3 was heated at 
75°C for 10 minutes, followed by GENECLEAN puri f icat ion. 
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A ligation cocktail was prepared: 
Sample 1 2 3 4 5 
Vector Ml 3 (/^ 1) 1 1 1 1 1 
Insert DNA (jul) 1 4 1 4 一 
T4 ligase buffer, (jitl) 1 l 1 1 1 
T4 ligase (/il) , 1 i i i i 
Water (/il) 6 3 6 3 7 
Sample 5 was used as control for vector• 
Competent ce l l s were prepared as the following: 
1. TGI, a s t rain of Escherichia coli for transformation of 
vector Ml3 was grown at 37。C with shaking overnight. 
A well isolated colony of TGI was inoculated in 5 ml of 
LB broth. 
2. After overnight incubation, 0.1 ml of TGI was 
inoculated to 21 ml of LB broth and incubated at 37。C 
for 3 hours with constant shaking. The culture was then 
cooled on ice for 15 minutes. The cel l pel le t obtained 
by centrifugation was resuspended in 10 ml of ice cold 
100 mM CaCl2. After 20 minute incubation on ice, the 
suspension was centrifuged and the cel l pel le t 
resuspended in 2 ml ice cold 100 mM CaCl2. To 5 /il of 
each ligation sample, 0.2 ml ce l l s was added for 
transformation• 
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3. Each pre-cooled polypropylene tube was added 200 /xl 
competent ce l ls , and 5 jul DNA cocktail . The sample 
mixture was then put into molten top agar (3 ml for 
each tube) and mixed with 40 /il 2.5% IPTG and 40 jul 2 
% X-Gal. 
4. The agar mixture was then poured onto a LB plate and 
allowed to set for a few minutes. 
5. The plate was incubated at 37。C overnight. 
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4• RESULTS 
4.1 DNA extraction 
Normal subject, CPP 
Several attempts were made to extract and purify genomic DNA 
from 10 ml fresh blood of a normal subject (CPP). The blood 
collected was carefully centrifuged to obtain a clear buffy 
coat layer which contained predominantly leucocytes and 
lymphocytes. Nucleic acids were prepared from th is buffy 
coat fract ion. 
The amount of genomic DNA obtained in the f i r s t attempt was 
quite sat isfactory. I t s OD 260/ OD 280 ra t io of was 1.77 
(Table 1) and i t s uv absorption spectrum from 250 nm to 300 
nm shown in (Fig 5). The absorption data suggested that th i s 
DNA sample contained very l i t t l e contamination of protein. 
I t was labelled CPP-1. 
A modification in extraction condition was made in the 
second attempt with the view to improve the DNA yield. 
Lysing buffer 2 was used. I t contained 5 mM EDTA instead of 
1 mM EDTA in lysing buffer 1 as used in the f i r s t attempt. 
The DNA sample obtained was labelled CPP-2, I t had a low OD 
26O/OD 280 ra t io of 1.39, which suggested the presence of 
considerable amount of protein. The uv spectrum (Figure 6) 
confirmed th i s , i . e . high absorption in the 280 nm region. 
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Table 1. Quantitation of DNA samples. The DNA yield was 
estimated by absorption at 260 nm. 
SAMPLE CPP-1 CPP-2 CPP-3 WPC-1 PCR-1-1 PCR-1-2 
DNA YIELD (ur) 48.50 52.00 20.90 \ 9 , 3.88 3,03 
OD260/QD280 1.77 1.39 1.87 1.83 . 2.43 3.56 
» 
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Although the DNA yield, on the basis of absorption at 260 
nm, was similar to that of the f i r s t attempt, the DNA was 
not as pure as the f i r s t sample CPP-1. Sample CPP-2 was 
therefore treated with phenol and phenol/chloroform again. 
The product had an OD 26O/OD 280 ra t io of 1.87 and renamed 
as CPP-3. I t was probably due to these further purification 
steps t the yield was low. However, i t s uv spectrum showed 
that there was less interference in the 280 nm region, a f te r 
the further treatment with phenol and phenol/chloroform 
(1:1)-
A satisfactory DNA preparation from the patient was, on the 
other hand, obtained using the same procedure (Table 1 and 
Figure 3 ). I t was labelled as WPC-1 and was subsequently 
used for PCR. 
4.2 Calibration of the Coy TempCycler 
Since preliminary PCR attempts carried out on the TempCycler 
(Coy) were not successful, i t was suspected that the 
assigned temperature on the machine has not been reached. 
The thermocycler was hence re-calibrated using a 1100 
thestoterm thermometer. The temperature probe was inserted 
direct ly into a PCR tube containing water and paraffin o i l . 
The tube was placed in the thermocycler. Three cycles of 
temperature programme were se t : 
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Denaturation: 91。C, 3 min 
Annealing: 60
0
C, 3 min 
Extension: 65
0
C, 3 min 
‘ 
The temperature was checked at 1一minute intervals . From the 
resul ts of Table 2, the actual temperature at the set point 
I 
for denaturation (91°C) was about 75。C, i t took one minute 
to reach 89°C and another two minutes to 91°C. The next set 
point was at 60°C, however, the actual temperature was s t i l l 
at 81°0, when the machine read 60°C two more minutes were 
needed to reach the actual set temperature of 6 0 T h e 
thermocycler was therefore re-calibrated for subsequent 
temperature programming. 
4.3 Optimization of PCR 
4.3.1 PCR-1: Photo 1 
Lane 1 and 10: 2 fj.1 Hae I I I Digest marker ( total 100 ng) 
Lane 2 and 3: 2 /-tl loading dye 
Lane 4 and 9: 5 jitl PCR-l-l 
Lane 5: 5 /il PCR-1-2 
Lane 6: 10 /il PCR-1-2 
Lane 7: 5 /il PCR-1-3 
Lane 8: 10 /^ 1 PCR-1-3 
Results: 
1. As the markers appeared smeared, the molecular weight 
of PCR products could not be rel iably estimated. 
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Table 2 Calibration of the Coy Tempcycler. The actual 
temperatures were recorded by an electronic 1100 thestoterm 
thermometer. 
SET ACTUAL ACTDAL ACTUAL ACTUAL 
CTCLE TEOMPERATTXRE TEMPERATURE TEMPERATimE, TEMPERATORE TEMPERATURE 
°C AT SET POINT AFTER 1 MIN, AFTER 2 MIN. AFTER 3 MIN. 
0
C °C OQ 
2 91 75.1 89.2 90.6 90.8 
60 81.2 61.6 60.1 59.8 
65 59,8 64^ 2 64.6 64.7 
2 91 75J 89.2 90.8 90.9 
60 82.1 62.0 . 60.2 59.9 
65 81.0 .. - 6L9_ 603 60.0 
3 91 75.7 89.4 90.8 90.9 
60 82.1 62.0 60.2 59.9 
- 65 60.1 64.3 64.8 64.9 
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band was detected in PCR-3-4 and PCR-3-5. The yield of 
amplification not improved using less MgGl2 in th is 
protocol. 
4.3.4 PCR-4： Photo 2 
Lane 1: loading buffer 
Lane 2: 3 jLtl PATX marker 
Lane 3: 2 /il PCR-4-2 
Lane 4： 2 /il PCR-4-2 
Lane 5: 2 /il PCR-4-3 
Lane 6: 2 PCR-4-4 
Lane 7: 2 jLtl PCR-4-1 
Results: 
1. Slight degradation on the molecular weight marker was 
shown on lane 2, separated DNA fragments had the 
molecular weight of 1300, 517, 396, 298, 221, 220, 150, 
145, and 75 base pairs. 
2. Two products amplified from template CPP-l were shown 
on lanes 3 and 4, similar yield were obtained at the 
position appropriate on the gel for 332 bp. 
3. in lane 5, the yield of PCR-4-3 prepared from WPC-l 
template was sl ightly less than other 3 lanes, however, 
less nonspecific smearing was observed. 
4. Other product amplified from CPP-3 template (PCR-4-4) 
showed similar yield. 
5. Results obtained in this experiment were, deemed 
satisfactory. 
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4.3.5 PCR-5： Photo 3 
Lane 1: loading buffer 
Lane 2: 3 /il Hae I I I Digest pBR322 DNA marker ( to ta l 420 ng) 
Lane 3: 1 /il PCR-5-1 
Lane 4 and 5: 1 /il PCR-5-2 
Lane 6, 7, and 8: 1 /il PCR-5-3 
Results: 
1. Separated DNA fragments in Hae I I I cut pBR 322 DNA: 
587, 540, 504, 458, 434, 267, 234, 213, 192, 184, 124, 
123, 104, 89, 80, 64, 57, 51, 21, 18, and 11 base pairs 
was used as marker. For the low molecular weight 
fragments， separation was not so obvious• The PCR 
product was si tuated at the expected position of 334 
bp, in between the 434 and 267 bp markers• 
2. Less amount of primer was used in t h i s experiment, but 
s ignif icant amplification was s t i l l obtained. 
3. In lanes 4 and 5, s l igh t nonspecific background was 
found at lower part of PCR product which might be due 
to the quali ty of template. 
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4.3.5 PCR-5： Photo 3 
Lane 1: loading buffer 
Lane 2: 2 /il Hae I I I Digest pBR322 DNA marker ( to ta l 280 ng) 
Lane 3 and 8: 2 /il PCR-6-1 
Lane 4: 2 /il PCR-6-2 
Lane 5: 2 /il PCR-6-3 
Lane 6: 2 /il PCR-6-4 
Lane 7: 2 pi PCR-6-5 
Results: 
1. Only half of the amount of template was used in PCR-6-2 
(lane 4) comparing with PCR-6-3 (lane 5), but s l igh t ly 
higher yield was obtained. The background smearing was 
s l igh t ly stronger in PCR-6-2. 
2. Comparing to PCR-5, PCR-6-3, PCR-6-5 had 5 fold 
increase in amount of primer, and 2-fold decrease in 
template, whilst PCR-6-2 and PCR-6-4 5-fold increase in 
primer and 4-fold decrease in template. No s ignif icant 
differences in terms of the yield were observed. 
3. Less nonspecific sitiealring was found in lanes 6 and 7, 
which were PCR products obtained from the haemophiliac 
pat ient . This was consistent with resu l t s of P C R - 5 . 
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4.3.5 PCR-5： Photo 3 
Lane 1; loading dye 
Lane 2: 2 /il Hae I I I Digest pBR3 22 DNA marker ( total 280 ng) 
Lane 3 and 10: 2 /xl PCR-7-1 
Lane 4: 2 jUl PCR-7-2 
Lane 5: 2 /il PCR-7-3 
Lane 6: 2 /zl PCR-7-4 
Lane 7 : 2 / / 1 PCR-7-5 
Lane 8: 2 /il PCR-7-6 
Lane 9: 2 /il PCR-7-7 
Results: 
1. The amounts of primer and template in PCR-7-2 and 
PCR-7-3 were same as PCR-6-2 and PCR-6-4 respectively. 
Better yield was obtained in th i s protocol which might 
be due to faster ramp time for the set point of 
temperature programme minimizing the nonspecific 
annealing. 
2. Both PCR-7-6 and PCR-7-7 had better yields and less 
nonspecific background compared with other pairs of 
samples. 
3. New batches of Taq DNA polymerase and amplification 
buffer were used. No contamination was found in the 
water control (lanes 3 and 10). 
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4.4 Purification of PCR Products 
GENECLEAN I I Kit BIO 101 
4.4.1 GC-1: Photo 6 
Lane 1: loading dye 
Lane 2: 3 /il PATX Hinf^ ^ marker 
Lane 3: 2 /xl Hae I I I Digest 0X-174-RF DNA marker ( total 100 
ng) 
Lane 4: 1 jul gene cleaned PCR-4-2 
Lane 5 : 1 / / 1 gene cleaned PCR-4-3 
Lane 6: 5 /il gene cleaned PCR-4-2 
Lane 7: 5 jLtl gene cleaned PCR-4-3 
The procedure recommended in the k i t was followed, but the 
yield was very low. No detectable DNA fragment was found in 
1 nl eluent on 5% (w/v) PAGE ‘ Eluent with 5 jul DNA fragment 
of PCR-4-2 and PCR-4-3 were degraded (lanes 6 and 7). More 
than 80% of the original DNA sample were los t . 
4.4.2 GC-2 
In th i s attempt very s t r i c t precaution had been taken: the 
Glassmilk suspension was thoroughly mixed, samples kept on 
ice throughout the purification procedure and so on. But no 
satisfactory improvement was made. The yield was s t i l l very 
low. 
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A trouble-shooting procedure was taken, and the products 
again analysed on PAGE. Faint bands were found near the 
region of PCR product, suggesting that the f i r s t and second 
elution were not complete. Another faint band was appeared 
in the eluent eluted from the Glassmilk, showing weak 
adsorption. 
4.4.3 GC-3: Photo 7 
Lane 1: 2 //1 Hae I I I Digest pBR322 DNA marker ( total 280 ng) 
Lane 2: 1 /il PCR-6-2, no GENECLEAN treatment 
Lane 3: 1 jul PCR-6-2 purified by GENECLEAN 
Lane 4: 1 /il PCR-6-3, no GENECLEAN treatment 
Lane 5: 1 /il PCR-6-3 purified by PAGE 
Lane 6: 1 /xl PCR-6-4, no GENECLEAN treatment 
Lane 7: 1 /il PCR-6-4 purified by GENECLEAN 
L a
ne 8: 1 jLtl PCR-6-5, no GENECLEAN treatment 
Lane 9: 1 /il PCR-6-5 purified by PAGE 
Results: 
1. Only a faint band was shown on lanes 3 and 6. 
2. Samples PCR-6-2, PCR-6-5, PCR-6-3 in lanes 2, 6, and 8 




 I n l a n e 4
,
 v e
r y faint band was observed which might be 
due to inappropriate loading of sample. 
4. Purification of PCR-6-2 and PCR-6-4 with GENECLEAN 
method showed very low recovery. 
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4.4.4 PAGE-1： Photo 7 
The same photograph was used as in GC-3. In lanes 5 and 9, 
more than 90% of PCR product were yielded from PAGE 
purif icat ion. Very clean bands were observed suggesting that 
th i s purification method was significantly better than the 
other two methods discussed previously. 
4.4.5 PAGE-2： Photo 8 
Lane 1: 2 /il Hae I I I Digest pBR322 DNA marker ( total 280 
ng) 
Lane 2: 1 jul PCR-7-2 before gene purification 
Lane 3: 1 jLtl PCR-7-2 purified by PAGE 
Lane 4: 1 jul PCR-7-3 before purification 
Lane 5: 1 jul PCR-7-3 purified by PAGE 
Lane 6: 1 /il PCR-7-4 before purification 
Lane 7: 1 /xl PCR-7-4 purified by PAGE 
Lane 8: 1 jul PCR-7-5 before purification 
Lane 9: 1 /il PCR-7-5 purified by PAGE 
Results: 
1* In lanes 2, 4, 6, and 8, samples were shown to have 
very low nonspecific background on the edges of wells 
and some fluorescent smearing on the lane. 
2. All purified products from lanes 3, 5 , 7 , and 9 gave 
sat isfactory yield of more than 90% recovery. 
3
- Purification of PCR products could be extracted from 
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, 
PAGE for subsequent experiments. 
4.4.6 Agarose Gel Extraction with Glasswool Exclusion: 
Photo 9 
Lane 1: loading dye 
Lane 2: 1 /il Hae I I I Digest pBR322 DNA marker ( total 140 ng) 
Lane 3: 1 /il out of 20 /il PCR product of PCR-4-3 
Result: 
The markers in lane 2 were somehow los t . 
2. Purification on agarose gel with glasswool exclusion 
shown on lane 3 was bet ter than samples in GC-1 and 
GC-3 lanes 3 and 7 by GENECLEAN, however, degraded 
bands appeared in th is method. 
4.5 Direct Sequencing of PCR product 
DS-l 
Self-prepared reagents were used, heat denaturation of DNA 
template followed by snap cool on liquid N2 was employed. 
However, no detectable bands were observed. 
DS-2 
Procedures and reagents of the
 35
Sequencing Kit obtained 
from Pharmacia was followed. However, no detectable bands 
were observed. 
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D S - 3 
Procedures and reagents of
 35
Sequencing Kit were used to 
repeat the direct sequencing again. Some nonspecific 
signals were appeared on the film, but more than one bands 
were appeared at the same level, 
D S - 4 
The same procedures and reagents were adopted as described 
in DS-3. However, higher amounts of template, enzyme and 
primer were used. Improved signals appeared on some level. 
Nevertheless, the intensity was too weak to enable the 




Only white plaques were observed on the LB agar plate. 
Cloning-2 
No plaques were formed. 
Cloning—3 
The vector Ml 3 was purified by GENECLEAN. The molecular 
weight of Ml3 i s about 700 bp, however, smears of bands were 
observed on PAGE. Only a few white plaques and much more 




5.1 DNA Extraction 
Different protocols have been used for DNA preparation from 
blood samples. Basically, most methods employed in the 
present study involve protein digestion by Proteinase K, RNA 
removal by RNase and multiple solvent extraction. They 
differ mainly in the details of reaction conditions. In one 
of the attempts, samples were f i r s t mixed vigorously by 
vortexing for a few minutes, then centrifuged at room 
temperature, 8000 X g for 20 minutes. After th is extraction, 
samples were found to be warm, I did not obtain good DNA. In 
separate attempt, the tubes were inverted gently and 
repeatedly for 3 minutes to f ac i l i t a t e mixing. These samples 
were centrifuged at 4
0
C, 4000 X g, f o r 10 minutes instead of 
20 minutes. By taking such precautions 7 i t appeared to be of 
some help in obtaining good DNA. The procedure modified by 
Blin and Stafford [31] which recommended to use a wide-bore 
pipette (0.3-cin-diameter orif ice) to transfer the aqueous 
phase to a microtube for phenol/phenol chloroform 
extraction, their recommendation was followed. 
5.2 Polymerase Chain Reaction 
To establish a reliable PCR,工 f o u n d that optimization of 
the PCR conditions is necessary. Important factors in 
achieving th is goal include quality of DNA as template, 
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concentration of primers, incubation time and temperature 
during the annealing and extension steps. Although i n i t i a l 
PCR conditions and temperature parameters during the f i r s t 
part of th is study were based on an established methodology 
[28], resul ts obtained were not entirely sat isfactory. 
Several attempts to optimize PCR were s t i l l necessary in 
order to obtain a protocol capable of producing positive and 
reproducible amplification resul t s . Once a workable protocol 
was developed, detai ls of conditions must be adhered 
s t r i c t l y . I found that the stringency of conditions was 
extremely important. Several technical precautions have to 
be taken. There must be absolute avoidance of carry-over of 
reagents. The Taq polymerase enzyme must be kept ' c lean
7
. 
New pipette t ips had been used in each aliquoting. Gloves 
and clean laboratory coats should be worn during the 
experiment, reagents were aliquoted and frozen for each 
experiment. 
of magnesium ion has been shown to have 
significant effect on the amplification process. I t may 
affect primer annealing, strand dissociation temperatures of 
both template and PCR product, product specif ic i ty , 
formation of primer-dimer a r t i f ac t s , and enzyme act ivi ty and 
f ide l i ty [32]. The presence of chelating agents such as EDTA 
or negatively charged ionic groups such as phosphates may 
affect the equilibration of magnesium ionization. However, I 
found no significant difference by changing the MgCl2 
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concentration of 10 fold difference in MgCl2. Meanwhile, the 
amount of purified DNA used as template in my PCR was quite 
high. As much as 550 ng of DNA was needed to give good 
amplification resul ts . Probably, the DNA preparations were 
not pure enough. 
Most of the published methods of PCR work on the FIX gene 
were carried out using a Cetus Thermocycler. The 
specification of th i s instrument, part icularly the speed of 
the temperature changes were different from the Coy 
TempCycler used in the present study. I Therefore needed to 
make some adjustments had to be made on the PCR temperature 
programme with different thermocyclers. I also found that 
the display temperature in my instrument was s l ight ly 
different from that of the actual temperature. I t was for 
th is reason, I re-calibrated the Coy TempCycler with an 
electronic thermometer. Hence, the thermocycler was found to 
be stable and consistent with performance, which were v i ta l 
x - • 
for development of PCR programmes. 
5.3 Purification of PCR Products 
To purify the amplified DNA material a f te r PCR, I used a 
GENECLEAN II k i t . I t has been used widely by many workers in 
different laboratories and i s shown to be convenient, rapid, 
simple and re l iable . I t has been claimed that more than 80% 
of the purified DNA fragment can be recovered, and 
58 
impurities such as RNAs, proteins, ethidium bromide, 
residual phenol, chloroform and unincorporated nucleotide 
and primers are removed effectively. However, I repeatedly 
obtained less than 50% yield• Sometimes over 90% of s tar t ing 
materials were . los t . A procedure for trouble-shooting was 
t r ied . The resul t showed that th i s excised DNA fragment die 
not bind to the GXassmilk effect ively. A second GENECLEAN 
II k i t was obtained from the supplier. But again poor yield 
and inconsistent resul ts were obtained. I t i s possible that 
my PCR product was too small, 332 bp, for effective 
adsorption onto the Glassmilk. The GENECLEAN manual did 
specify that a 80% yield should be obtained for DNA fragment 
larger than 500 bp. GENECLEAN of other PCR products more 
than 300 bp in length have produced more than 50% yield in 
th is laboratory [33]. The introduction of agarose gel 
extraction with glasswool as exclusion medium led to a 
better yield. However, s l ight degradation of the DNA 
fragment was found in repeated t r i a l s . This procedure was 
simple to set up, but the time required for preparation and 
elution was long. Extraction of DNA from the polyacrylamide 
gel a f te r electrophoresis was found to be an easy-to-handle 
method. In repeated t r i a l s recoveries of DNA were 
consistently higher than 90%. The drawback i s that th is i s 
not an exhaustive purification procedure. The DNA band on 
the gel which was excised for DNA extraction might obtain 
other materials adhering to the DNA product and 
electrophoreses to the same position. However, th i s was the 
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only purification procedure which gave consistent good 
recoveries. I used th is method to prepare DNA for subsequent 
DNA sequencing experiment, 
5.4 Sequencing 
Sequencing experiments u t i l iz ing a commonly supplied reagent 
k i t were not successful. The DNA extracted from the 
polyacrylamide gel was used directly for sequencing af te r 
alkalination. Although the sequencing procedures were 
followed s t r i c t l y and repeated several times. I always 
obtained very dark bands at the top of the gel, with faint 
bands at the lower part• Moreover, there are bands in more 
than one track at the same level. since the dXTP/ddXTP 
rat ios of th i s
 35
Sequencing k i t were not provided, I was 
unable to manipulate their concentrations to improve the 
sequencing reactions. I thus switched to a protocol based on 
a published method [28] and made up a l l reagents by myself. 
Unfortunately the reactions again did not work. The fai lure 
of these experiments were probably due to the poor quality 
of the DNA template, which was not suff ic ient ly pure. 
5•5 Cloning 
I intended to clone the PCR DNA of FIX promoter into Ml3 
phage as th i s could produce large amount of DNA which could 
be purified for sequencing. To f ac i l i t a t e cloning of the 
amplified DNA into M13, selected res t r ic t ion s i t es can be 
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incorporated at the 5' ends of the amplification primers. 
For the f i r s t attempt for cloning, only a few white plaques 
were observed on LB agar plate which indicated that the 
vector-insert ligation had failed to take place. The vector 
could have self- l igated prior to phosphatase treatment. One 
of the most likely causes is that the molar ra t io of vector 
DNA to insert DNA was not desirable for ligation to proceed. 
This might be rect i f ied by repeating the ligations at a 
range of vector-insert rat ios . Another likely cause is that 
the insert material contained ligase inhibitors or has 
unsuitable ends. 
The second cloning experiment was also unsuccessful. There 
was no formation of plaques, indicating a very low 
transfection efficiency, the competent cel ls might be too 
old to be used. In the third cloning attempt new competent 
cel ls were prepared. But s t i l l only very few white plaques 
appeared, other plaques were blue. This indicated that 
either the ligase has low act ivi ty, or the restr ic t ion 
enzyme had failed to digest the vector, leaving closed 
circular material, i . e . re-ligation of the vector which 
gives blue plaques regardless of subsequent phosphatasing. 
On agarose gel electrophoresis of the vector, smear band was 
found af ter GENECLEAN. 
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6• CONCLUSION 
In th i s study I established protocols for DNA extraction and 
PCR amplification of a DNA fragment in the human FIX 
promoter. Unfortunately, sequencing and cloning experiments 
were unsuccessful. Consequently, the sequences of the 
amplified products could not be confirmed or compared with 
published data. I t was unfortunate that the GENECLEAN Kit 
did not work. As a resul t , DNA of suff ic ient purity for 
direct sequencing was unable to obtain. Since the laboratory 
was just s tar ted for molecular cloning experiments i t 
probably took a l i t t l e b i t longer than one expected time to 
establish these techniques and arrange f a c i l i t i e s . Due to 
time constrains the cloning experiments were not confirmed. 
Further attempts should be made to establish protocols for 
cloning the PCR product so that suff ic ient DNA could be 
prepared and purified for sequencing reactions. More 
haemophilia B patients should be recruited for sequence 
comparison study and characterization although there are 
very few documented haemophilia B patients in Hong Kong. 
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